BioSpace News Archive

Noctrix Health, Inc. today announced that the first patient has been enrolled in a multi-center, randomized controlled clinical trial. The RESTFUL Study (ClinicalTrials.gov Identifier: NCT04874155)

CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, today announced that it will hold a webcast with the investment community on Thursday, May 27, at 5 p.m. Eastern Daylight Time.

SafeRX Pharmaceuticals Inc. , a company developing an ARO (Alcohol Resistant Opioid) platform for preventing opioid/alcohol-related deaths, announced today that it is launching an equity crowdfunding campaign via Regulation CF to raise funds for its patented solution to this dimension of the national health crisis.

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced today that the U.S. Food and Drug Administration (FDA) posted briefing documents for the May 27, 2021 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC)

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Celanese Corporation (NYSE: CE), a global specialty materials company, today announced plans to explore the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery.

Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, announced a new peer-reviewed study published using the Tapestri Platform’s single-cell multi-omics solution to accurately distinguish leukemic cells from clonal hematopoiesis of indeterminate potential in relapsed AML patients.

Professor Lyon brings decades of experience in semiconductor physics and engineering to EeroQ’s novel quantum computing chip design

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative drug discovery in immuno-oncology, announced today the completion of $40 million Series B financing

NextPhase Medical Devices LLC, a leading provider of electronic manufacturing services (EMS) and single-use disposable devices to leading medical device OEMs, recently announced the acquisition of Proven Process Medical Devices Inc.

Innovative program will provide critical capabilities and help accelerate global scaling of Canadian sector